Ritter Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RTTR) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.69▼$0.7450-Day Range$0.45▼$4.0952-Week Range$0.15▼$1.27Volume10,244 shsAverage Volume14.23 million shsMarket Capitalization$33.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media About Ritter Pharmaceuticals Stock (NASDAQ:RTTR)Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.Read More RTTR Stock News HeadlinesSeptember 15, 2023 | health.usnews.comKristen RitterJuly 8, 2023 | health.usnews.comDr. Harold K. RitterDecember 5, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comJuly 1, 2023 | bizjournals.comDenver Business Journal welcomes new tech reporterApril 10, 2023 | usatoday.comJason Ritter and Drew Barrymore's raw conversation on her show may matter more than you thinkMarch 29, 2023 | thestreet.comRitter Pharmaceuticals Changing the Game With Lactose Intolerance TreatmentMarch 18, 2023 | finance.yahoo.comGlobal Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second GenomeJanuary 19, 2023 | yahoo.comMelanie Lynskey's husband Jason Ritter will join her in Yellowjackets this seasonDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 16, 2022 | finance.yahoo.comMicrobiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsightMay 24, 2021 | au.finance.yahoo.comDocbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEOApril 18, 2021 | investing.comQualigen Therapeutics Inc (QLGN)June 10, 2020 | finance.yahoo.comQualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19June 4, 2020 | finance.yahoo.comQualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS™ TechnologyMay 22, 2020 | seekingalpha.comRitter to complete Qualigen tie-up todayMay 22, 2020 | apnews.comRitter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.May 22, 2020 | finance.yahoo.comRitter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.May 19, 2020 | finance.yahoo.comRitter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.May 14, 2020 | finance.yahoo.comRitter Pharmaceuticals, Inc. Announces Adjournment of its Special MeetingMay 11, 2020 | www.benzinga.comRitter Pharmaceuticals Regains Compliance with Nasdaq's Stockholders' Equity Requirement for Continued ListingMay 11, 2020 | finance.yahoo.comRitter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued ListingMay 7, 2020 | www.nasdaq.comRTTR Ritter Pharmaceuticals, Inc. Common StockMay 7, 2020 | www.msn.com66 Biggest Movers From YesterdayMay 7, 2020 | www.benzinga.comThinking about buying stock in Stemline Therapeutics, KLX Energy, Trinity Biotech, Tilray, or Ritter Pharmaceuticals?May 6, 2020 | finance.yahoo.comLeading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger ProposalsMay 1, 2020 | finance.yahoo.comRitter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020April 28, 2020 | finance.yahoo.comRitter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.See More Headlines Receive RTTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2020Today12/05/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RTTR CUSIPN/A CIK1460702 Webwww.ritterpharmaceuticals.com Phone310-203-1000FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,130,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.05% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book7.01Miscellaneous Outstanding Shares46,153,000Free FloatN/AMarket Cap$32.33 million OptionableNot Optionable Beta-0.43 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Ira Eliot Ritter (Age 70)Co-Founder, Exec. Chairman & Chief Strategic Officer Mr. Andrew J. Ritter (Age 36)Co-Founder, CEO, Pres, Corp. Sec. & Director Mr. Michael D. Step (Age 59)Consultant & Director Mr. John W. Beck CPA (Age 59)CPA, Chief Financial Officer Ms. Ellen F. Mochizuki (Age 52)Consultant Key CompetitorsSol-Gel TechnologiesNASDAQ:SLGLBeyondSpringNASDAQ:BYSISELLAS Life Sciences GroupNASDAQ:SLSKinetaNASDAQ:KADaré BioscienceNASDAQ:DAREView All Competitors RTTR Stock Analysis - Frequently Asked Questions How were Ritter Pharmaceuticals' earnings last quarter? Ritter Pharmaceuticals Inc (NASDAQ:RTTR) released its earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. When did Ritter Pharmaceuticals' stock split? Ritter Pharmaceuticals shares reverse split on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Ritter Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and When did Ritter Pharmaceuticals IPO? (RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager. This page (NASDAQ:RTTR) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.